Description：Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3].
IC50 & Target：Bacterial[1][2][3].
In Vitro：Nemonoxacin (0–5.51 µM; 24 h) shows good antibacterial activity in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nemonoxacin Related Antibodies
- MRP2 Antibody
- Elongation factor 2 Antibody (YA962)
- Elongation factor 2 Antibody (YA964)
- PU.1/SPI1 Antibody (YA1116)
- Sulfadimidine Antibody (YA906)
- Elongation factor 2 Antibody (YA963)
- Anthrax Protective gen Antibody (YA1060)
- Elongation factor 1 gamma Antibody (YA2004)
- Pulmonary Surfactant Associated Protein D Antibody (YA2107)
- Cathelicidin Antibody (YA2380)
- Elongation Factor Ts Antibody (YA2524)
- Elongation Factor 1A2 Antibody (YA2879)
- BPI Antibody (YA3068)
- MetRS Antibody (YA3196)
Cell Viability Assay[1]
Cell Line:MSSA, MRSAConcentration:0–5.51 µM (0–2048 µg/mL)Incubation Time:24 hResult:Inhibited MSSA and MRSA with MIC90 values of 0.12 and 4 µg/mL.
In Vivo：Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates[2].
Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:CD-1 ICR mice (18–22 g; mouse systemic infection model)[2].Dosage:1.6–4.0 mg/kg (S. aureus and S. capitis infections), 2.4–10.0 mg/kg (S. pneumonia infections), 5.0–22.6 mg/kg (E. faecalis infections), 1.6–10.0 mg/kg (E. coli infections)Administration:Oral administration; 15 min and 6 h after infectionResult:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively.
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT02205112TaiGen Biotechnology Co., Ltd.
Community-acquired Pneumonia
June 2014Phase 3NCT01944774TaiGen Biotechnology Co., Ltd.|QPS-Qualitix|R&G Pharma Studies Co.,Ltd.
Pneumonia
March 2013Phase 2NCT01529476TaiGen Biotechnology Co., Ltd.|Qualitix Clinical Research Co., Ltd.|Parexel|PPD
Pneumonia
April 2011Phase 3
Molecular Weight：371.43
Formula：C20H25N3O4
CAS No.：378746–64–6
Appearance：Solid
Color：White to off-white
SMILES：O=C(C1=CN(C2CC2)C3=C(C=CC(N4C[C@@H](N)C[C@H]©C4)=C3OC)C1=O)O
Shipping：Room temperature in continental US; may vary elsewhere.
Storage:Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months-20°C1 month
Solvent & Solubility
In Vitro:
DMSO : 2 mg/mL (5.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Preparing:Stock Solutions
ConcentrationSolventMass1 mg5 mg10 mg1 mM2.6923 mL13.4615 mL26.9230 mL5 mM0.5385 mL2.6923 mL5.3846 mL
View the Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.